Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D1.74 - Molecular IgE sensitization profiling in a patient with Asteraceae weed pollen allergy and anaphylaxis to honey
D1.75 - Anaphylaxis during Picc Line replacement
D1.76 - The Hot Chocolate Drink Dilemma
D1.77 - Perioperative Hypersensitivity Outcomes: A retrospective review of 112 patients seen between 2019 and 2024 at two allergy centres
D1.78 - Analytical Verification of Omega-5 gliadin (Tri a 19) Allergen Assay on the IMMULITE 2000 XPi System*
D1.79 - Cardiovascular symptoms during anaphylaxis: An analysis from the European Anaphylaxis Registry
D1.82 - Diagnostic challenges in amoxicillin-clavulanate anaphylaxis: an inconclusive in vitro study – Case Report
D1.83 - Asthma and multi-food allergy were risk factors for Oral Food Challenge failure
D1.84 - IgE-mediated allergy to chlorhexidine: case report
D1.85 - Basophil activation test in β-Lactam Anaphylaxis: A Case Series from a Tertiary Hospital
D1.86 - Hypersensitivity Reaction to Lugol’s Solution: A Case Report
D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria
D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series
D1.376 - Emerging inmunomodulatory agents for atopic dermatitis
D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report
D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis
D1.379 - AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)
D1.380 - Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow
D1.383 - Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report
D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download